^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    HDAC3 inhibitor

    Related drugs:
    Apply
    A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers (NCT04708470)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    10/05/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    PD-L1 • CD4
    |
    PD-L1 negative
    |
    Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC
    Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia (NCT05881265)
    Phase 2
    Shanghai Jiao Tong University School of Medicine
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    05/15/2023
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    RARA • PML
    |
    Venclexta (venetoclax) • Epidaza (chidamide)
    Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic (NCT02115282)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    03/29/2014
    Primary completion :
    05/05/2020
    Completion :
    06/25/2025
    HER-2 • ER • PGR
    |
    exemestane • Jingzhuda (entinostat) • goserelin acetate
    Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (NCT01038778)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    10/29/2009
    Primary completion :
    05/22/2019
    Completion :
    07/30/2025
    mTOR
    |
    Jingzhuda (entinostat) • Proleukin (aldesleukin)
    Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas (NCT03179930)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    01/24/2025
    Initiation :
    06/07/2017
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    CTLA4
    |
    Keytruda (pembrolizumab) • Jingzhuda (entinostat)
    Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma (NCT05958719)
    Phase 2
    Institute of Hematology & Blood Diseases Hospit...
    Recruiting
    Last update posted :
    12/30/2024
    Initiation :
    03/02/2023
    Primary completion :
    12/30/2026
    Completion :
    03/02/2027
    IFNG • IL6 • TNFA • IL10 • IFNA1
    |
    azacitidine • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)
    Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia (NCT06532552)
    Phase 2
    The First Affiliated Hospital of Soochow Univer...
    Recruiting
    Last update posted :
    11/20/2024
    Initiation :
    07/29/2024
    Primary completion :
    08/01/2027
    Completion :
    08/01/2028
    BCL2
    |
    Venclexta (venetoclax) • azacitidine • Epidaza (chidamide) • cladribine
    Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma (DEL Biomarker) (NCT06652152)
    Phase N/A
    Ruijin Hospital
    Not yet recruiting
    Last update posted :
    10/22/2024
    Initiation :
    10/30/2024
    Primary completion :
    05/30/2025
    Completion :
    12/30/2025
    BCL2
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Epidaza (chidamide)
    Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. (NCT06563778)
    Phase 2
    Chinese PLA General Hospital
    Not yet recruiting
    Last update posted :
    08/21/2024
    Initiation :
    09/01/2024
    Primary completion :
    09/01/2026
    Completion :
    09/01/2028
    PD-1
    |
    decitabine • Adcetris (brentuximab vedotin) • Epidaza (chidamide) • bendamustine
    Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma (NCT04674683)
    Phase 3
    HUYABIO International, LLC.
    Active, not recruiting
    Last update posted :
    06/24/2024
    Initiation :
    08/12/2021
    Primary completion :
    12/01/2024
    Completion :
    10/01/2025
    BRAF
    |
    PD-L1 expression • BRAF mutation • PD-L1 negative
    |
    Opdivo (nivolumab) • Epidaza (chidamide)
    Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma. (NCT06393361)
    Phase 2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    06/01/2024
    Primary completion :
    06/01/2026
    Completion :
    06/01/2027
    PD-1
    |
    carboplatin • gemcitabine • ifosfamide • etoposide IV • decitabine • pegylated liposomal doxorubicin • Adcetris (brentuximab vedotin) • Epidaza (chidamide)
    PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma (NCT05083208)
    Phase 1/2
    Henan Cancer Hospital
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    02/20/2022
    Primary completion :
    06/30/2024
    Completion :
    01/01/2027
    ALK
    |
    ALK positive • ALK negative
    |
    Epidaza (chidamide) • parsaclisib (INCB50465)
    Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. (CA209-117) (NCT01928576)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Completed
    Last update posted :
    05/03/2024
    Initiation :
    11/06/2013
    Primary completion :
    04/04/2023
    Completion :
    04/04/2023
    EGFR • KRAS • ALK
    |
    EGFR mutation • EGFR exon 19 deletion • ALK positive • ALK rearrangement • EGFR wild-type • ALK wild-type • ALK translocation
    |
    Opdivo (nivolumab) • azacitidine • Jingzhuda (entinostat) • Onureg (azacitidine oral)
    Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer (NCT01349959)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    04/05/2024
    Initiation :
    04/21/2011
    Primary completion :
    03/27/2014
    Completion :
    03/07/2025
    HER-2 • ER • PGR
    |
    HR positive • PGR negative
    |
    azacitidine • Jingzhuda (entinostat)
    Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents (NCT02936752)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/25/2024
    Initiation :
    06/23/2017
    Primary completion :
    10/01/2022
    Completion :
    03/21/2025
    CD4
    |
    Keytruda (pembrolizumab) • Jingzhuda (entinostat)
    Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer (ETCTN-9844) (NCT02453620)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/20/2024
    Initiation :
    02/12/2016
    Primary completion :
    04/22/2021
    Completion :
    08/30/2024
    HER-2 • CD86
    |
    HR positive • HER-2 negative
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Jingzhuda (entinostat) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Chidamide Bridging for CAR-T Therapy (NCT05370547)
    Phase 1/2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    03/06/2024
    Initiation :
    05/25/2022
    Primary completion :
    06/30/2024
    Completion :
    06/30/2025
    BCL2 • BCL6 • PMAIP1
    |
    CD19 positive
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Epidaza (chidamide) • fludarabine IV • Carteyva (relmacabtagene autoleucel)
    Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) (KEPIDA-2) (NCT05833724)
    Phase 2
    Great Novel Therapeutics Biotech & Medicals Cor...
    Recruiting
    Last update posted :
    02/26/2024
    Initiation :
    04/01/2024
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    ALK
    |
    ALK positive • ALK negative
    |
    Epidaza (chidamide)
    INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (INFORM2 NivEnt) (NCT03838042)
    Phase 1/2
    University Hospital Heidelberg
    Recruiting
    Last update posted :
    02/07/2024
    Initiation :
    05/26/2020
    Primary completion :
    06/30/2026
    Completion :
    06/30/2027
    PD-L1 • TMB • MYC
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Jingzhuda (entinostat)
    A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL (ABC) (NCT06220487)
    Phase 2
    Nanfang Hospital, Southern Medical University
    Recruiting
    Last update posted :
    01/24/2024
    Initiation :
    02/01/2024
    Primary completion :
    12/31/2025
    Completion :
    01/01/2028
    ABL1
    |
    Blincyto (blinatumomab) • prednisone • Epidaza (chidamide) • Nailike (olverembatinib)
    Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib (CINDERELLA) (NCT05464173)
    Phase 1/2
    Biyun Wang, MD
    Recruiting
    Last update posted :
    01/22/2024
    Initiation :
    07/01/2022
    Primary completion :
    02/01/2025
    Completion :
    05/01/2025
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • fulvestrant • Epidaza (chidamide)
    Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC) (NCT05281276)
    Phase 1
    Taipei Medical University Shuang Ho Hospital
    Recruiting
    Last update posted :
    12/14/2023
    Initiation :
    09/20/2022
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    KRAS
    |
    KRAS mutation • RAS mutation • RAS wild-type
    |
    Epidaza (chidamide) • celecoxib oral
    Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (DONIMI) (NCT04133948)
    Phase 1/2
    The Netherlands Cancer Institute
    Active, not recruiting
    Last update posted :
    11/15/2023
    Initiation :
    01/07/2020
    Primary completion :
    01/11/2022
    Completion :
    11/01/2024
    IFNG
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • domatinostat (4SC-202)
    Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia (NCT05566054)
    Phase 2
    The First Affiliated Hospital of Soochow Univer...
    Recruiting
    Last update posted :
    11/09/2023
    Initiation :
    03/01/2022
    Primary completion :
    09/30/2024
    Completion :
    09/30/2025
    BCL2
    |
    Venclexta (venetoclax) • azacitidine • Epidaza (chidamide)
    Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer (NCT02718066)
    Phase 1b/2
    HUYABIO International, LLC.
    Completed
    Last update posted :
    11/09/2023
    Initiation :
    08/01/2016
    Primary completion :
    09/01/2023
    Completion :
    09/01/2023
    EGFR • PD-L1 • ALK
    |
    Opdivo (nivolumab) • Epidaza (chidamide)
    A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients (NCT06087419)
    Phase 1/2
    Institute of Hematology & Blood Diseases Hospit...
    Not yet recruiting
    Last update posted :
    11/02/2023
    Initiation :
    10/30/2023
    Primary completion :
    12/30/2024
    Completion :
    12/30/2025
    CD22
    |
    CD22 expression
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Besponsa (inotuzumab ozogamicin) • Epidaza (chidamide)
    Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer (NeoTEE) (NCT04465097)
    Phase 2
    First Affiliated Hospital, Sun Yat-Sen University
    Completed
    Last update posted :
    10/17/2023
    Initiation :
    07/08/2020
    Primary completion :
    10/01/2023
    Completion :
    10/01/2023
    ER
    |
    ER positive • HER-2 negative
    |
    Epidaza (chidamide) • exemestane • goserelin acetate
    Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (NCT02780804)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/17/2023
    Initiation :
    01/06/2017
    Primary completion :
    06/30/2021
    Completion :
    09/30/2021
    AFP
    |
    Jingzhuda (entinostat)
    Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (ENCORE 601) (NCT02437136)
    Phase 1b/2
    Syndax Pharmaceuticals
    Completed
    Last update posted :
    09/21/2023
    Initiation :
    07/01/2015
    Primary completion :
    09/29/2022
    Completion :
    09/29/2022
    PD-L1 • BRAF • ALK • MSI
    |
    EGFR mutation • BRAF mutation • BRAF V600 • ALK positive • ALK rearrangement
    |
    Keytruda (pembrolizumab) • Jingzhuda (entinostat)
    Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL (NCT04022005)
    Phase 2
    Sun Yat-sen University
    Completed
    Last update posted :
    09/11/2023
    Initiation :
    06/19/2019
    Primary completion :
    11/16/2022
    Completion :
    03/11/2023
    CD20
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • Epidaza (chidamide)
    Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL (NCT04231448)
    Phase 3
    Chipscreen Biosciences, Ltd.
    Active, not recruiting
    Last update posted :
    09/06/2023
    Initiation :
    05/21/2020
    Primary completion :
    07/05/2023
    Completion :
    03/01/2025
    MYC • BCL2 • CD20 • BCL6
    |
    CD20 positive • MYC rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide) • cyclophosphamide intravenous
    Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer (NCT05983107)
    Phase 2
    Cancer Institute and Hospital, Chinese Academy ...
    Recruiting
    Last update posted :
    08/09/2023
    Initiation :
    07/20/2023
    Primary completion :
    07/15/2026
    Completion :
    07/15/2027
    HER-2 • ER • PIK3CA • PGR
    |
    HR positive • HER-2 negative • PIK3CA mutation • PGR positive • PIK3CA wild-type
    |
    everolimus • tamoxifen • fulvestrant • Epidaza (chidamide) • goserelin acetate
    A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL (NCT05931263)
    Phase 3
    The First Affiliated Hospital with Nanjing Medi...
    Recruiting
    Last update posted :
    07/04/2023
    Initiation :
    06/01/2023
    Primary completion :
    02/01/2026
    Completion :
    02/01/2028
    CD34
    |
    cytarabine • etoposide IV • Epidaza (chidamide) • carmustine • melphalan
    A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy (NCT05890287)
    Phase N/A
    Tianjin Medical University Cancer Institute and...
    Recruiting
    Last update posted :
    06/06/2023
    Initiation :
    05/16/2023
    Primary completion :
    05/01/2026
    Completion :
    10/01/2026
    HER-2
    |
    HER-2 negative
    |
    tamoxifen • fulvestrant • letrozole • Epidaza (chidamide) • anastrozole • exemestane
    A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy (NCT05527912)
    Phase 2
    Sun Yat-sen University
    Recruiting
    Last update posted :
    04/25/2023
    Initiation :
    02/24/2023
    Primary completion :
    09/01/2024
    Completion :
    12/01/2024
    MYC • BCL2
    |
    BCL2 expression • MYC expression
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • Epidaza (chidamide)
    Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer (NCT05808582)
    Phase 2
    The First Affiliated Hospital with Nanjing Medi...
    Not yet recruiting
    Last update posted :
    04/14/2023
    Initiation :
    05/01/2023
    Primary completion :
    09/01/2023
    Completion :
    09/01/2024
    HER-2 • ER • PGR
    |
    ER positive • HR positive • HER-2 negative
    |
    fulvestrant • Epidaza (chidamide)
    Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy (NCT05806047)
    Phase 2
    Fudan University
    Not yet recruiting
    Last update posted :
    04/10/2023
    Initiation :
    05/01/2023
    Primary completion :
    05/01/2024
    Completion :
    11/01/2024
    ER
    |
    fulvestrant • Epidaza (chidamide)
    Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure (NCT05335473)
    Phase 1/2
    Henan Cancer Hospital
    Recruiting
    Last update posted :
    04/06/2023
    Initiation :
    05/13/2022
    Primary completion :
    05/01/2025
    Completion :
    11/01/2025
    HER-2
    |
    HER-2 negative
    |
    Halaven (eribulin mesylate) • Epidaza (chidamide)
    Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC (NCT05768503)
    Phase 3
    Sun Yat-sen University
    Recruiting
    Last update posted :
    03/14/2023
    Initiation :
    03/01/2023
    Primary completion :
    01/01/2026
    Completion :
    01/01/2027
    MSI • MLH1 • MSH6 • MSH2
    |
    Avastin (bevacizumab) • 5-fluorouracil • Tyvyt (sintilimab) • oxaliplatin • irinotecan • Epidaza (chidamide) • leucovorin calcium
    Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer (NCT05163483)
    Phase 2
    Ruihua Xu
    Recruiting
    Last update posted :
    03/06/2023
    Initiation :
    07/01/2022
    Primary completion :
    12/01/2023
    Completion :
    12/01/2025
    PD-L1 • PD-L2
    |
    Avastin (bevacizumab) • Loqtorzi (toripalimab-tpzi) • Epidaza (chidamide)